We are pioneers in harnessing bacteria as a novel and revolutionary class of medicines: Live Biotherapeutics

We understand that bacteria in the human gastrointestinal (GI) tract - known as the gut microbiome - have important functions in many diseases, not just those in the gut.

Importantly, we understand how specific strains of bacteria function and mechanisms of host-microbe interactions. Leveraging rational, mechanism-driven hypotheses, driven by our world-leading MicroRx® platform, we are developing a revolutionary new class of drug - known as Live Biotherapeutic Products (LBPs).

  • We are targeting a new, safer approach to drug development
  • We are a fully integrated microbiome company with the capability to progress from research to production to clinic
  • We understand mechanism: how our products exert their therapeutic effects and act as a drug
  • We have developed and wholly own the largest intellectual property estate in the field

  • We have laid foundations that have positioned 4D pharma to transform the sector; with four clinical programs delivering data and a number of development programs in exciting new areas progressing towards the clinic, 4D pharma is taking the lead in defining the microbiome space.

    What makes 4D pharma different?

    We understand that the bacteria of the gut microbiome have an important function in health and disease, but importantly – we understand how they function, and how they can be used as potential new therapies.

    4D pharma is taking the microbiome beyond the gut. The multi-faceted MicroRx® platform and our deep understanding of bacterial functionality has enabled us to develop Live Biotherapeutics for a large number of diseases including cancer, gastrointestinal disease, respiratory disease and conditions of the central nervous system (CNS).

    Watch our video below to find out more about our approach.

    Find out more